
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
AMPLITUDE SURGIC. EO -,01 1AU FR0012789667
AB/FROM ONWARDS 12.03.2025 11:47 CET
© 2025 Xetra Newsboard
Realtime | Geld | Brief | Zeit |
---|---|---|---|
3,440 | 3,580 | 24.04. |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
17.04. | Amplitude Surgical - 9-Months Consolidated Sales for FY 2024-25 of €83.8m, up +6.4% at Constant Exchange Rates |
Sales up +6.6% at constant exchange rates in Q3 FY 2024-25
Consolidated sales for 9 months up+ 6.4% at constant exchange rates to €83.8m
Good momentum in France: sales up +4.7% over... ► Artikel lesen | |
17.04. | Zydus Lifesciences Limited announces the execution of undertakings to tender as part of its envisaged tender offer for Amplitude Surgical SA shares | AHMEDABAD, India and PARIS, April 17, 2025 /PRNewswire/ -- Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the execution of... ► Artikel lesen | |
17.04. | Amplitude Surgical Has Been Informed by Zydus Lifesciences Limited of the Execution of Undertakings to Tender as Part of Its Envisaged Tender Offer for Amplitude Surgical SA Shares | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible).
Following the announcement of the envisaged tender offer on March 11, 2025 of Zydus Lifesciences Limited... ► Artikel lesen | |
26.03. | Amplitude Surgical Announces H1 2024-25 Results: 51.5 M€ Sales and 13.1 M€ EBITDA |
Consolidated sales of €51.5m, up 6.3% at constant exchange rates
EBITDA up 10.6% to €13.1 million, EBITDA margin 25.4%
Current operating income of €6.0 million
Cash position... ► Artikel lesen | |
12.03. | XFRA 1AU: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |